Medline gets FDA warning, 340B restrictions vacated
Supply Chain Pulse — 2026-04-10
Medline faces an FDA warning letter after more than 200 complaints about its angiographic syringes used in heart procedures—a reminder that even bedrock suppliers aren't immune to quality failures. Meanwhile, a federal court just vacated HRSA's decade-old policy restricting how 340B hospitals can purchase drugs through GPOs, potentially saving covered entities millions in procurement costs. Between manufacturing stumbles and regulatory wins, it's shaping up as a week where your vendor relationships and purchasing strategies deserve fresh scrutiny.
Quick Hits
- Henry Ford Health acquires 25-location Cornerstone Medical Group (Modern Healthcare)
- Companies still await clarity on tariff refund processes after court ruling (Supply Chain Dive - Healthcare)
- MedStar, CommonSpirit address clinician trust issues with AI implementation (Modern Healthcare)
- Premier showcases pharmacy compounding excellence at two member hospitals (Premier Inc News)
Medline receives FDA warning letter on heart procedure syringes
The FDA issued a warning letter to Medline following more than 200 complaints about its angiographic syringes used in cardiac catheterization procedures. A December 2025 inspection found manufacturing practice violations at Medline facilities, raising quality concerns for a critical device used in life-saving heart procedures that many cath labs rely on daily.
Federal court strikes down HRSA's 340B hospital drug purchasing restrictions
A federal judge vacated HRSA's policy that prevented 340B hospitals from using "replenishment models" to purchase drugs through GPOs at discounted rates. The decade-old restriction forced hospitals to buy drugs upfront at higher prices before accessing 340B discounts, potentially costing covered entities significant savings on pharmaceutical procurement.
Advocate Health launches drone delivery network starting in Charlotte
The 67-hospital system will deploy Zipline drones for medical deliveries, beginning in Charlotte before expanding to Chicago and Milwaukee markets. While still emerging technology, drone delivery could eventually reshape how hospitals handle urgent lab samples, blood products, and critical medications across multi-site health systems.
Iran conflict raises concerns about pharmaceutical supply chains
Industry experts are monitoring potential supply chain disruptions as Iran tensions escalate, though immediate impacts remain limited. While many active pharmaceutical ingredients come from regions that could be affected by broader Middle East instability, the advice for supply chain leaders is measured vigilance rather than panic buying.
Transpacific shipping rates climb amid geopolitical uncertainty
Ocean freight rates are rising across transpacific routes as the Iran conflict adds uncertainty to global shipping, though demand has softened in recent weeks. For healthcare organizations importing medical devices or pharmaceutical ingredients from Asia, this could signal higher logistics costs ahead even as overall shipping volumes decline.
Source: Supply Chain Dive - Healthcare
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe